2025. Pembrolizumab in PD-L1-positive advanced non-small cell lung carcinoma: A meta-analysis of survival benefits and immune-related toxicity events patterns: Original scientific article. ADMET and DMPK. 13, 5 (Oct. 2025). DOI:https://doi.org/10.5599/admet.2956.